<DOC>
	<DOCNO>NCT02665910</DOCNO>
	<brief_summary>Condition : Rheumatoid Arthritis Intervention : Drug : SHR0302 ; Drug : SHR0302 placebo comparator Phase : Phase 1 Study Type : Interventional Study Design : Treatment , Parallel Assignment , Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) , Randomized</brief_summary>
	<brief_title>Multiple Doses Escalation Study SHR0302 Rheumatoid Arthritis ( RA ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female subject 18~70 year age day sign informed consent , Have diagnosis RA meeting 1987 ACR/EULAR criterion RA ACR functional class IIII , Body mass index ( BMI = weight/height square ( kg/m2 ) ) within range 19 30 , Have agree use anti rheumatic drug except study drug study period . Current therapy disease modify antirheumatic drug ( DMARD ) , exception Methotrexate ( MTX ) , Leflunomide , sulfasalazine , antimalarial , gold preparation , penicillamine , must discontinue period least 7 t1/2s prior dose , Previous RA treatment DMARDs drug strong immunosuppressive effect 3 month prior dose ( 12 month rituximab B cell deplete agent ) , Previous therapy NSAIDs oral glucocorticoid 2 week dose , Any parenteral ( intramuscular intravenous injection ) intraarticular corticosteroid therapy 4 week dose , Previous treatment interferon 4 week dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>